Literature DB >> 15446308

Characterization of the role of major histocompatibility complex in type 1 diabetes recurrence after islet transplantation.

Holly Y Young1, Peter Zucker, Richard A Flavell, Anthony M Jevnikar, Bhagirath Singh.   

Abstract

BACKGROUND: Major histocompatibility complex (MHC) molecules are essential determinants of beta-cell destruction in type 1 diabetes (T1D). MHC class I- or class II-null nonobese diabetic (NOD) mice do not spontaneously develop autoimmune diabetes and are resistant to adoptive transfer of disease. Both CD4+ and CD8+ T cells are associated with graft destruction after syngeneic islet transplantation. MHC molecules within the graft (i.e., on beta-cells or donor lymphocytes) may influence the interactions between antigen presenting cells and effector T cells and, therefore, the survival outcome of the graft.
METHODS: Donor islets from NOD mice deficient in one or both of beta2-microglobulin and class II transactivator genes were transplanted into diabetic NOD mice. Immunohistochemistry was performed to identify the phenotype of infiltrating cells and to assess graft insulin production. The presence of cytokines in the grafts was assayed by reverse transcription polymerase chain reaction.
RESULTS: MHC class II-null islets demonstrated rates of rejection comparable with control wild-type (wt) islets. In contrast, MHC class I- and II-null islets demonstrated indefinite survival (over 100 days). Infiltrates of both failed and surviving grafts were comprised of cytotoxic lymphocytes (CTL), helper T cells, and macrophages. Grafts also showed the presence of both Th1- and Th2-type cytokines (interleukin [IL]-2, IL-4, IL-10, and interferon-gamma), independent of graft status.
CONCLUSIONS: These results demonstrate the primary importance of MHC class I molecules in the pathogenesis of diabetes recurrence postislet transplantation. Conversely, MHC class II expression is not a necessary mechanistic component of transplant destruction. In addition, these results implicate MHC class I-restricted CTLs but not MHC class II-restricted T cells in disease recurrence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15446308     DOI: 10.1097/01.tp.0000128907.83111.c6

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.

Authors:  Julie B Sneddon; Qizhi Tang; Peter Stock; Jeffrey A Bluestone; Shuvo Roy; Tejal Desai; Matthias Hebrok
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

2.  CD4+ T cells are sufficient to elicit allograft rejection and major histocompatibility complex class I molecule is required to induce recurrent autoimmune diabetes after pancreas transplantation in mice.

Authors:  Zhidan Xiang; Lian-Li Ma; Santhakumar Manicassamy; Balaji B Ganesh; Phillip Williams; Ravi Chari; Anita Chong; Deng-Ping Yin
Journal:  Transplantation       Date:  2008-04-27       Impact factor: 4.939

3.  Increased numbers of low-oxygenated pancreatic islets after intraportal islet transplantation.

Authors:  Richard Olsson; Johan Olerud; Ulrika Pettersson; Per-Ola Carlsson
Journal:  Diabetes       Date:  2011-07-25       Impact factor: 9.461

Review 4.  Making the most of major histocompatibility complex molecule multimers: applications in type 1 diabetes.

Authors:  Greg S Gojanovich; Paul R Hess
Journal:  Clin Dev Immunol       Date:  2012-05-28

5.  Alpha-Lipoic Acid Inhibits Spontaneous Diabetes and Autoimmune Recurrence in Non-Obese Diabetic Mice by Enhancing Differentiation of Regulatory T Cells and Showed Potential for Use in Cell Therapies for the Treatment of Type 1 Diabetes.

Authors:  Shing-Hwa Huang; Shun-Li Kuo; Shyi-Jou Chen; Jeng-Rong Lin; Yuan-Wu Chen; Zhi-Jie Hong; Huey-Kang Sytwu; Gu-Jiun Lin
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

6.  A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection.

Authors:  Ping Wang; Mehmet V Yigit; Chongzhao Ran; Alana Ross; Lingling Wei; Guangping Dai; Zdravka Medarova; Anna Moore
Journal:  Diabetes       Date:  2012-08-24       Impact factor: 9.461

Review 7.  Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases.

Authors:  Gu-Jiun Lin; Shing-Hwa Huang; Shyi-Jou Chen; Chih-Hung Wang; Deh-Ming Chang; Huey-Kang Sytwu
Journal:  Int J Mol Sci       Date:  2013-05-31       Impact factor: 5.923

8.  Reversal of autoimmunity by mixed chimerism enables reactivation of β cells and transdifferentiation of α cells in diabetic NOD mice.

Authors:  Shanshan Tang; Mingfeng Zhang; Samuel Zeng; Yaxun Huang; Melissa Qin; Ubaydah Nasri; Pere Santamaria; Arthur D Riggs; Liang Jin; Defu Zeng
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.